|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we demonstrated that necrosis-inducing peptide P16 kills human glioblastoma cancer cells and primary human hepatoma or renal cancer cells isolated from patients who had not responded to standard treatments.
|
31206614 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of FHIT and p16 genes and proteins in HCC tissues were obviously lower than those in cancer-adjacent tissues (P<0.05 in all comparisons).
|
30655841 |
2019 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results warrant further investigation of Rb and p16 expression as markers of HCC sensitivity to ribociclib.
|
31250364 |
2019 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
CONCLUSIONS The methylation of p16 and FHIT genes was an independent risk factor for hepatocellular carcinoma.
|
30773529 |
2019 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The abnormal methyation level of the p16 gene promoter could be a promising marker for the detection of HCC.
|
30942220 |
2019 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Compared with paracancerous tissue, normal liver tissue, cirrhosis, and chronic hepatitis B as controls, the pooled ORs of P16 promoter region methylation in HBV-related HCC cancer tissues were 7.18 (95% CI =2.31-22.33), 24.89 (95% CI =3.38-183.03), 5.92 (95% CI =1.78-19.68), and 12.12 (95% CI =0.75-196.50).
|
30254471 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> HCC pathogenesis affecting p16 methylation don't work during normal blood, when from benign diseases to HCC bloods, can produce powerful role.
|
29896276 |
2018 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As the data suggested, multivariate cox regression analysis revealed that the recurrence-free survival of 46 patients was greatly associated with portal vein tumor thrombus (PVTT) and p16 methylation and receiver operating characteristic (ROC) curves demonstrated that the predictive range of portal vein tumor thrombus (PVTT) combined with p16 hypermethylation was more sensitive than that of either PVTT or p16 hypermethylation alone with regard to disease recurrence in patients with HCC, which could be testified as a valuable biomarker in Clinical application.
|
29516551 |
2018 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Similarly, silencing of EZH2 by siRNA down-regulated P14, P15, P16 mRNA levels and inhibited HCC cell proliferation.
|
28928088 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
No association was found between p16 methylation or alteration and the prognosis of patients with HCC in overall survival (OS) and disease-free survival (DFS).
|
28930859 |
2017 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In vitro experiments using the human HCC cell lines revealed that K19 silencing suppressed cell growth by inducting apoptosis or upregulating p16 and p27, resulting in cellular senescence.
|
27863477 |
2016 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, we identified a potential role for nuclear-cytoplasmic shuttling in p16-stimulated migration, consistent with the predominantly cytoplasmic localization of p16 in IHC-positive HCC samples.
|
23894465 |
2013 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MARVELD1 inhibited cell proliferation and enhance chemosensitivity via increasing expression of p53 and p16 in hepatocellular carcinoma.
|
22320884 |
2012 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The antitumor potency of P16 by downregulating the Akt/survivin signalling was also demonstrated in HCC xenograft models in nude mice.
|
20971978 |
2011 |
|
Liver carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular alterations such as the p53 mutation, p16 gene silencing, and AKT signaling activation are found in the late stage of HCC progression.
|
21829019 |
2011 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
P16 hypermethylation induces the inactivation of p16 gene, plays an important role in hepatocarcinogenesis, and is associated with an increased risk of HCC and liver cirrhosis.
|
21799651 |
2011 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The difference of CDKN2A-methylation and p16 protein expression between HCCs and liver metastases was statistically significant (p < 0.01, respectively).
|
20569442 |
2010 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of p16 was one of the most important alterations in SVR-HCC.
|
18492017 |
2009 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since loss of p16 is closely related to functional inactivation of p27 in HCC, investigating both p16 and p27 may be useful for precise prognostic predictions in individuals with HCC.
|
18350604 |
2008 |
|
Liver carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, p16 methylation was associated with a poor survival after surgery for recurrent stage I to II hepatocellular carcinomas (hazard ratio, 4.05; 95% confidence interval, 1.15-14.20; P = 0.03).
|
18723830 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The hypermethylation frequency of GSTP1 and RASSF1A showed significant difference between HCCs and liver cirrhosis with or without HBV infection (P<0.05), but differences of the hypermethylation status of APC, E-cadherin, and P16 were not statistically significant.
|
18691570 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lentiviral-mediated Smad4 RNAi induced anti-proliferation by p16 up-regulation and apoptosis by caspase 3 down-regulation in hepatoma SMMC-7721 cells.
|
18949401 |
2008 |
|
Liver carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the promoter hypermethylation of P15 and P16 was associated with elevated serum AFP levels in 35 HCC samples with CIMP+ (P<0.05).
|
17289889 |
2007 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It suggested that epigenetic alteration of the EDNRB and p16 genes may play an important role in the pathogenesis of HCC.
|
16391877 |
2006 |
|
Liver carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results in this study also showed that the frequency of antibodies to p16 is relatively higher in nasopharyngeal cancer (28.6%), breast cancer (17.1%) and hepatocellular carcinoma (HCC, 21.4%).
|
17016600 |
2006 |